

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Offic**Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/481,990	01/11/00	LESAJE	F 989.6351DIV

022469 HM32/0924  
SCHNADER HARRISON SEGAL & LEWIS, LLP  
1600 MARKET STREET  
SUITE 3600  
PHILADELPHIA PA 19103

EXAMINER  
LANDSMAN, R

ART UNIT	PAPER NUMBER
1647	

DATE MAILED: 09/24/01

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/481,990	LESAGE ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Robert Landsman	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 22 June 2001.
- 2a) This action is **FINAL**.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-26 is/are pending in the application.
- 4a) Of the above claim(s) 1-10 and 14-26 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 11 and 12 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

- |  |  |
|--|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                    | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)           | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ . | 6) <input type="checkbox"/> Other: _____ .                                   |

## **DETAILED ACTION**

### ***1. Formal Matters***

- A. A copy of the Foreign Priority Document, filed 7/16/01, has been entered into the record.
- B. Amendment B, filed 6/22/01, has been entered into the record.
- C. Claims 1-26 are pending. Claims 1-10 and 14-26 have been withdrawn from consideration. Claim 13 has been canceled. Therefore, claims 11 and 12 are pending.
- D. All Statues under 35 USC not cited in this Office Action can be found, cited in full, in a previous Office Action.

### ***2. Election/Restriction***

- A. In Paper No. 4, the Examiner restricted claims 11-13 into group II and claims 9 and 15-19 into Group III. The Examiner stated that these Groups are related as a product and process of use and that the protein can be used as an immunogen to make an antibody. Applicants argued this restriction requirement in Paper No. 5 stating that the lack of utility of the claimed protein argued by the Examiner would not constitute the basis for restriction. The Examiner stated in Paper No.6 that the restriction is proper since these Groups are related as product and process of use. This restriction was also made FINAL in Paper No. 6. Applicants argue in Paper No. 7 that the Examiner provides only one example of the use of this protein (e.g. immunogen) in the restriction requirement and, therefore, that the two Groups should be combined.

These arguments have been considered, but are not deemed persuasive. Applicants already state, via the claims, that this protein can be used in a screening process. This constitutes one use of the protein. The use of the protein as an immunogen, as stated by the Examiner, would be a second use of this protein. The protein could also be used in the treatment of patients, or for antibody and ligand purification.

Art Unit: 1647

Therefore, this restriction is deemed proper and is made FINAL. However, if the protein is found to be allowable, then the methods of screening ligands would be *rejoined as long as these method claims are commensurate in scope with the elected protein claims and do not raise any issues under 35 USC 112.*

## **Withdrawn Objections**

A. The objection to the specification regarding “Brief Description of Drawings” has been withdrawn since Applicants have added this heading in the specification.

## **Withdrawn Claim Rejections**

### ***1. Claim Rejections - 35 USC § 112, second paragraph***

A. The rejection of claims 11 and 12 under 35 USC 112, second paragraph regarding the indefiniteness of “properties and structure of a TWIK-1-type channel” has been withdrawn since Applicants removed this language from the claims.

## **Maintained Rejections**

### ***1. Claim Rejections - 35 USC § 101***

A. Claims 11 and 12 remain rejected under 35 USC 101 for the reasons already of record on pages 4-5 of the Office Action dated 3/20/01. Applicants argue that the restriction requirement of Paper No. 4 implies that the protein of the present invention has a specific utility since it can be used as an immunogen. Applicants also argue that the specification also discloses that the abundance of TWIK-1 proteins in numerous tissues confer its role in potassium transport, therefore, providing a new means of screening drugs and preventing diseases. Applicants’ arguments have been considered, but are not deemed persuasive.

Art Unit: 1647

The use of the protein as an immunogen to make antibodies does not confer utility on the protein. This rejection is not in conflict with the current utility guidelines. The instant application has provided a description of a partially isolated protein. However, the instant application does not disclose the biological role of this protein or its significance. It is clear from the instant specification that the claimed receptor is termed an "orphan receptor" in the art. There is little doubt that, after complete characterization, this protein will probably be found to have a patentable utility. This further characterization, however, is part of the act of invention and, until it has been undertaken, Applicants' claimed invention is incomplete.

The instant situation is directly analogous to that of which was addressed in *Brenner v. Manson*, 148 U.S.P.Q. 689 (Sus. Ct, 1966), in which a novel compound which was structurally analogous to other compounds which were known to possess anticancer activity was alleged to be potentially useful as an antitumor agent in the absence of evidence supporting this utility. The court expressed the opinion that all chemical compounds are "useful" to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of "useful" as it appears in 35 U.S.C. 101, which required that an invention must have either an immediate obvious or fully disclosed "real-world" utility. The court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility," "[u]nless and until a process is refined and developed to this point - where specific benefit exists in currently available form – there is insufficient justification for permitting an applicant to engross what may prove to be a broad field," and "a patent is not a hunting license," "[i]t is not a reward for the search, but compensation for its successful conclusion."

The instant claims are drawn to a protein which has a yet undetermined function or biological significance. However, there is no actual and specific significance which can be attributed to said protein identified in the specification. For this reason, the instant invention is incomplete. In the absence of a knowledge of the natural ligands or biological significance of this protein, there is no immediately

Art Unit: 1647

obvious patentable use for it. To employ a protein of the instant invention in the identification of substances which bind to and/or mediate activity of the said receptor is clearly to use it as the object of further research which has been determined by the courts to be a non-patentable utility. Since the instant specification does not disclose a "real-world" use for said protein, then the claimed invention is incomplete and, therefore, does not meet the requirements of 35 U.S.C. 101 as being useful.

These claims are directed to isolated and purified polypeptides encoding supposed potassium channel proteins. The specification discloses isolated polynucleotide clones encoding potassium channel proteins which have significant sequence similarity to known potassium channel receptors. Based on the structural similarity, the specification asserts that the newly disclosed protein has similar activities.

The assertion that the disclosed proteins have biological activities similar to known potassium channel proteins cannot be accepted in the absence of supporting evidence, because the relevant literature reports examples of polypeptide families wherein individual members have distinct, and sometimes even opposite, biological activities.

In the transforming growth factor (TGF) family, Vukicevic et al. (1996, PNAS USA 93:9021-9026) disclose that OP-1, a member of the TGF- family of proteins, has the ability to induce metanephrogenesis, whereas closely related TGF- family members BMP-2 and TGF- 1 had no effect on metanephrogenesis under identical conditions (p. 9023, paragraph bridging columns 1-2). See also Massague, who reviews other members of the TGF- family (1987, Cell 49:437-8, esp. p. 438, column 1, second full paragraph to the end). Similarly, PTH and PTHrP are two structurally closely related proteins which can have opposite effects on bone resorption (Pilbeam et al., 1993, Bone 14:717-720; see p. 717, second paragraph of Introduction). Finally, Kopchick et al. (U.S. Patent 5,350,836) disclose several antagonists of vertebrate growth hormone that differ from naturally occurring growth hormone by a single amino acid (column 2, lines 37-48).

Generally, the art acknowledges that function cannot be predicted based solely on structural similarity to a protein found in the sequence databases. For example, Skolnick et al. (2000, Trends in Biotech. 18:34-39) state that knowing the protein structure by itself is insufficient to annotate a number of functional classes, and is also insufficient for annotating the specific details of protein function (see Box 2, p. 36). Similarly, Bork (2000, Genome Research 10:398-400) states that the error rate of functional annotations in the sequence database is considerable, making it even more difficult to infer correct function from a structural comparison of a new sequence with a sequence database (see especially p. 399). Such concerns are also echoed by Doerks et al. (1998, Trends in Genetics 14:248-250) who state that (1) functional information is only partially annotated in the database, ignoring multi functionality, resulting in underpredictions of functionality of a new protein and (2) overpredictions of functionality occur because structural similarity often does not necessarily coincide with functional similarity. Smith et al. (1997, Nature Biotechnology 15:1222-1223) remark that there are numerous cases in which proteins having very different functions share structural similarity due to evolution from a common ancestral gene. Brenner (1999, Trends in Genetics 15:132-133) argues that accurate inference of function from homology must be a difficult problem since, assuming there are only about 1000 major gene superfamilies in nature, then most homologs must have different molecular and cellular functions. Finally, Bork et al. (1996, Trends in Genetics 12:425-427) add that the software robots that assign functions to new proteins often assign a function to a whole new protein based on structural similarity of a small domain of the new protein to a small domain of a known protein. Such questionable interpretations are written into the sequence database and are then considered facts.

Therefore, based on the discussions above concerning the specific examples of structurally similar proteins that have different functions, along with the art's recognition that one cannot rely upon structural similarity alone to determine functionality, the specification fails to teach the skilled artisan the

Art Unit: 1647

utility of the claimed protein of SEQ ID NO:2 which is only known to be homologous to known potassium channel proteins.

**2. Claim Rejections - 35 USC § 112, first paragraph – enablement**

A. Claims 11 and 12 remain rejected under 35 USC 112, first paragraph, for the reasons already of record on pages 5-6 of the Office Action dated 3/20/01 as well as for the reasons stated in the above rejection under 35 USC 101. Applicants argue that the claimed invention is enabled because it has utility as argued previously. Applicants' arguments have been fully considered, but are not found to be persuasive for the reasons discussed above.

\* These references are not the basis of a new rejection, but only to provide support in the rebuttal of Applicants' arguments to the rejection under 35 USC 101.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1647

***Advisory information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (703) 306-3407. The examiner can normally be reached on Monday - Friday from 8:00 AM to 5:00 PM (Eastern time) and alternate Fridays from 8:00 AM to 5:00 PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242. Fax draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Robert Landsman, Ph.D.

Patent Examiner

Group 1600

September 21, 2001

*Gary L. Kunz*  
GARY L. KUNZ  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600